Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
9.89
-0.91 (-8.39%)
Mar 31, 2025, 1:11 PM EDT - Market open

Company Description

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.

The company’s lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases.

The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept.

Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Keros Therapeutics, Inc.
Keros Therapeutics logo
Country United States
Founded 2015
IPO Date Apr 8, 2020
Industry Biotechnology
Sector Healthcare
Employees 169
CEO Jasbir Seehra

Contact Details

Address:
1050 Waltham Street, Suite 302
Lexington, Massachusetts 02421
United States
Phone 617 314 6297
Website kerostx.com

Stock Details

Ticker Symbol KROS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001664710
CUSIP Number 492327101
ISIN Number US4923271013
Employer ID 81-1173868
SIC Code 2834

Key Executives

Name Position
Dr. Jasbir S. Seehra Ph.D. Chief Executive Officer and Chair of the Board
Christopher Rovaldi M.Sc. President and Chief Operating Officer
Keith C. Regnante MBA Chief Financial Officer
Esther Cho J.D. Senior Vice President, General Counsel and Secretary
Robin Wagner Senior Vice President of Human Resources
John Oram M.B.A. Senior Vice President of Program and Portfolio Management
Dr. Yung H. Chyung M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 31, 2025 8-K Current Report
Mar 6, 2025 8-K Current Report
Feb 28, 2025 8-K Current Report
Feb 26, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 26, 2025 10-K Annual Report
Feb 26, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G Filing
Feb 7, 2025 SCHEDULE 13G/A Filing
Jan 30, 2025 8-K Current Report
Jan 21, 2025 8-K Current Report